Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference

October 2, 2018

STRASBOURG, France--(BUSINESS WIRE)--Oct 2, 2018--Regulatory News:

Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies, will be presenting three posters highlighting the Company’s world-leading viral vector expertise and their potential to transform the fight against cancer at the annual meeting of the Society for Immunotherapy of Cancer (SITC) to be held November 7-11 in Washington DC (USA).

They will cover:

Invir.IO TM: a new generation of multifunctional oncolytic viruses; myvac TM: an individualized immunotherapy based on a viral vector (MVA); a next generation viral vector for cancer immunotherapy (PCPV).

Invir.IO TM

Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment

Authors: Marchand JB, Semmrich M, Fend L, Tornberg UC, Silvestre N, Frendéus B, Quéméneur E Poster number: P615

myvac TM

Viral based vaccine for highly personalized neoantigen-directed cancer therapies

Authors: Ottensmeier C, Savelyeva N, McCann K, Wang C, Greenbaum J, Finn CN, Hoffmann C, Schultz H, Silvestre N, Marchand JB, Quéméneur E, Bendjama K Poster number: P148


Pseudocowpox virus (PCPV), a potent tumor antigen-independent viral vector for cancer immunotherapy

Authors: Rittner K, Tosch C, Thioudellet C, Remy-Ziller C, Claudepierre MC, Sansas B, Foloppe J, Erbs P, Silvestre N, Bendjama K, Quéméneur E Poster number: P181

The posters will be on display both Friday, November 9 and Saturday, November 10 in the Poster Hall (Hall E).

About Transgene Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s lead clinical-stage programs are: TG4010, a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine against HPV-positive head and neck cancers. The Company has several other programs in clinical development, including TG1050 (a therapeutic vaccine for the treatment of chronic hepatitis B) and TG6002 (an oncolytic virus for the treatment of solid tumors). With its proprietary Invir.IO TM, Transgene builds on its expertise in viral vectors engineering to design a new generation of multifunctional oncolytic viruses. Myvac TM, an individualized MVA-based immunotherapy integrating neoantigens, completes this innovative research portfolio. Additional information about Transgene is available at www.transgene.fr. Follow us on Twitter: @TransgeneSA

Disclamer This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results, regulatory authorities’ agreement with development phases, and development. The Company’s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance, or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Document de Référence, available on the AMF website ( ) or on Transgene’s website ( ). Forward-looking statements speak only as of the date on which they are made and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181001006022/en/

CONTACT: Transgene:

Lucie Larguier, +33 (0)3 88 27 91 04

Director Corporate Communications & IR




Citigate Dewe Rogerson

David Dible / Marine Perrier, + 44 (0)20 7638 9571




SOURCE: Transgene

Copyright Business Wire 2018.

PUB: 10/02/2018 01:30 AM/DISC: 10/02/2018 01:30 AM


Update hourly